ALX Oncology News and Activities

ALX Oncology is a company listed under the stock ticker ALXO (US).

View the org chart displaying its 20 main executives

Most searched biographies at ALX Oncology

• Jason Lettmann, Chief Executive Officer
• Corey Goodman, Executive Chairman of the Board
• Rekha Hemrajani, Director

Popular executive movements at ALX Oncology

• Marija Vrljic, Vice President, Antibody Technologies, has left the company  (posted on May 6 2026).
• Jeff Knight has joined the company as Chief Development and Operations Officer  (posted on April 13 2026).
• Alan Sandler who is Chief Medical Officer, will become Director  (posted on September 15 2025).

Click here to view some more movements at ALX Oncology

Create your alert
to follow the executive moves at ALX Oncology.

ALX Oncology has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Patrick Enright - Director at CuraSen Therapeutics

Learn more about the Biotechnology industry

Press releases by ALX Oncology

• ALX Oncology’s Evorpacept Receives Fast Track Designation from FDA as First-Line Treatment for Head and Neck Squamous Cell Carcinoma – ALX Oncology
• ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloid Leukemia – ALX Oncology
• ALX Oncology Announces Evorpacept Clinical Program Updates – ALX Oncology
• ALX Oncology to Participate in the Jefferies 2022 Healthcare Conference – ALX Oncology
• ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights – ALX Oncology
• ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma – ALX Oncology
• ALX Oncology Announces Upcoming Virtual Investor Conference Participation – ALX Oncology
• ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights – ALX Oncology
• ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma – ALX Oncology
• ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer – ALX Oncology
• View more press releases Close

Social media about ALX Oncology

• ALX Oncology on Wikipedia, Google News & Yahoo Finance
• ALX Oncology on LinkedIn, X (Twitter) & YouTube